HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bomanji, J. Articles by Besser, G.M. Search for Related Content PubMed PubMed Citation Articles by Bomanji, J. Articles by Besser, G.M.

A Scintigraphic Comparison of Iodine-123-Metaiodobenzylguanidine and an Iodine-Labeled Somatostatin Analog (Tyr-3-Octreotide) in Metastatic Carcinoid Tumors

Departments of Nuclear Medicine, Endocrinology and Pediatric Oncology, St. Bartholomew's Hospital, London, United Kingdom

Correspondence: For reprints contact: Dr. J. Bomanji, Department of Nuclear Medicine, St. Bartholomew's Hospital, West Smithfield, London EC1A 7BE, U.K.

ABSTRACT

A number of neoplasms are known to express somatostatin receptors, and the use of somatostatin receptor imaging in their localization has recently been described. We compared an ¹²³I-labeled somatostatin analog Tyr-3-octreotide (TOCT) and ¹²³I-labeled metaiodobenzylguanidine (MIBG) scintigraphy in seven patients with histologically proven metastatic carcinoid tumors. The optimum time for identifying tumor uptake on scanning after [¹²³I]MIBG was 24–48 hr, and after ¹²³I-TOCT 10–30 min postinjection. Both radiopharmaceuticals showed a varying spectrum of tracer uptake ([¹²³I]MIBG showed no uptake in one patient; minimal in two; moderate in two; and intense in two; ¹²³I-TOCT showed no uptake in two patients; minimal uptake in one; moderate uptake in two; and intense uptake in two). In two patients, ¹²³I-TOCT identified metastatic lesions not seen by [¹²³I]MIBG scintigraphy. These preliminary results suggest that [¹²³I]MIBG and ¹²³I-TOCT are useful and complementary imaging techniques for detecting metastatic carcinoid tumors.

This article has been cited by other articles:

				G. Kaltsas, M. Korbonits, E. Heintz, J. J. Mukherjee, P. J. Jenkins, S. L. Chew, R. Reznek, J. P. Monson, G. M. Besser, R. Foley, et al. Comparison of Somatostatin Analog and Meta-Iodobenzylguanidine Radionuclides in the Diagnosis and Localization of Advanced Neuroendocrine Tumors J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 895 - 902. [Abstract] [Full Text]